XML 97 R32.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Commitments | 12 Months Ended
--- | ---
Nov. 30, 2023
Disclosure of commitments [abstract] |
Commitments |
26. | Commitments
| (a) | Long-term procurement agreements and research agreements
The Company has long-term procurement agreements with third party suppliers in connection with the commercialization of EGRIFTA SV ® and Trogarzo ® . As at November 30, 2023, the Company had outstanding purchase orders and minimum payments required under these agreements amounting to $14,682 (2022 – $1,644) for the manufacture of Trogarzo ® , EGRIFTA SV ® and for other various services. As at November 30, 202 3 , the Company also ha d research commitments and outstanding clinical material purchase orders amounting to $807 (2022 – $ 1,310 ) in connection with the oncology platform and nil (2022 – $868) in connection with a new formulation of tesamorelin and of a multi-dose pen injector developed for this new formulation.
| (b) | Licence agreement
On February 3 , 2020, the Company entered into an amended and restated licence agreement with the Massachusetts General Hospital (“MGH”), as amended on April 15, 2020, in order to benefit from its assistance and knowledge for the development of tesamorelin for the potential treatment of Non-Alcoholic Steatohepatitis (“NASH”) in the general population. Under the terms of the amended agreement, the MGH, through Dr. Steven Grinspoon, will provide services related to the study design, selection of optimal patient population, dosing, study duration and other safety matters and participate, if need be, in regulatory meetings with the FDA or the EMA. In consideration, the Company agreed to make certain milestone payments to the MGH related to the development of tesamorelin and to pay a low single-digit royalty on all sales of EGRIFTA SV ® above a certain amount. The payment of the royalty will begin upon approval by the FDA or the EMA (the first to occur) of an expanded label of tesamorelin for the treatment of any fatty liver disease, including Non-Alcoholic Fatty Liver Disease or NASH in the general population.

X
- Definition The disclosure of commitments. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfCommitmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of commitments abstract. + References No definition available. + Details
Name: | thtx_DisclosureOfCommitmentsAbstract
Namespace Prefix: | thtx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration